These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 20467214)

  • 1. A historical perspective on the discovery of statins.
    Endo A
    Proc Jpn Acad Ser B Phys Biol Sci; 2010; 86(5):484-93. PubMed ID: 20467214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The discovery of statins.
    Stossel TP
    Cell; 2008 Sep; 134(6):903-5. PubMed ID: 18805080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy.
    Steinberg D
    J Lipid Res; 2006 Jul; 47(7):1339-51. PubMed ID: 16585781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Jim's view: What makes transformative basic science possible?
    Rothman JE
    FEBS Lett; 2019 Aug; 593(15):1877-1878. PubMed ID: 31301063
    [No Abstract]   [Full Text] [Related]  

  • 5. Stents, statins, and other dumb luck.
    Robbins P
    J Biol Chem; 2011 Jan; 286(3):1669-74. PubMed ID: 21098482
    [No Abstract]   [Full Text] [Related]  

  • 6. History of the cholesterol controversy in Britain.
    Thompson GR
    QJM; 2009 Feb; 102(2):81-6. PubMed ID: 19042967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Discovery of Statins.
    Manu P; Rogozea L
    Am J Ther; 2016; 23(4):e980-1. PubMed ID: 27386961
    [No Abstract]   [Full Text] [Related]  

  • 8. From fungus to pharmaceuticals--the chemistry of statins.
    McPherson PA
    Mini Rev Med Chem; 2012 Oct; 12(12):1250-60. PubMed ID: 22512563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A conversation with P. Roy Vagelos. Interview by Ushma S. Neill.
    Vagelos PR
    J Clin Invest; 2014 Jun; 124(6):2291-2. PubMed ID: 24892701
    [No Abstract]   [Full Text] [Related]  

  • 10. Stents and statins: history, clinical outcomes and mechanisms.
    Nair PK; Mulukutla SR; Marroquin OC
    Expert Rev Cardiovasc Ther; 2010 Sep; 8(9):1283-95. PubMed ID: 20828351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins: in the beginning.
    Lyons KS; Harbinson M
    J R Coll Physicians Edinb; 2009 Dec; 39(4):362-4. PubMed ID: 20509462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins.
    Lahera V; Goicoechea M; de Vinuesa SG; Miana M; de las Heras N; Cachofeiro V; Luño J
    Curr Med Chem; 2007; 14(2):243-8. PubMed ID: 17266583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antioxidative actions of statins: potential mechanisms for antiathersclerotic effects.
    Watanabe T; Yasunari K; Nakamura M
    Mini Rev Med Chem; 2006 May; 6(5):505-8. PubMed ID: 16719823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brown and Goldstein: the cholesterol chronicles.
    Nair P
    Proc Natl Acad Sci U S A; 2013 Sep; 110(37):14829-32. PubMed ID: 23980185
    [No Abstract]   [Full Text] [Related]  

  • 15. The statins in preventive cardiology.
    Steinberg D
    N Engl J Med; 2008 Oct; 359(14):1426-7. PubMed ID: 18832243
    [No Abstract]   [Full Text] [Related]  

  • 16. Goals of statin therapy: three viewpoints. 2002.
    Thompson GR; Packard CJ; Stone NJ
    Atheroscler Suppl; 2004 Oct; 5(3):107-14. PubMed ID: 15531283
    [No Abstract]   [Full Text] [Related]  

  • 17. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994.
    Pedersen TR; Kjekshus J; Berg K; Haghfelt T; Faergeman O; Faergeman G; Pyörälä K; Miettinen T; Wilhelmsen L; Olsson AG; Wedel H;
    Atheroscler Suppl; 2004 Oct; 5(3):81-7. PubMed ID: 15531279
    [No Abstract]   [Full Text] [Related]  

  • 18. Statins, cholesterol, and the prevention of coronary heart disease.
    Freeman MW
    FASEB J; 2006 Feb; 20(2):200-1. PubMed ID: 16449790
    [No Abstract]   [Full Text] [Related]  

  • 19. Foundations for blockbuster drugs in federally sponsored research.
    Thompson RB
    FASEB J; 2001 Aug; 15(10):1671-6. PubMed ID: 11481212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin converting enzyme (ACE) and HydroxyMethylGlutaryl-CoA (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium.
    Chłopicki S; Gryglewski RJ
    Pharmacol Rep; 2005; 57 Suppl():86-96. PubMed ID: 16415489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.